[go: up one dir, main page]

EA200300438A1 - Иммуномодулирующие пептиды, полученные из белков теплового шока, и их применение - Google Patents

Иммуномодулирующие пептиды, полученные из белков теплового шока, и их применение

Info

Publication number
EA200300438A1
EA200300438A1 EA200300438A EA200300438A EA200300438A1 EA 200300438 A1 EA200300438 A1 EA 200300438A1 EA 200300438 A EA200300438 A EA 200300438A EA 200300438 A EA200300438 A EA 200300438A EA 200300438 A1 EA200300438 A1 EA 200300438A1
Authority
EA
Eurasian Patent Office
Prior art keywords
immune
modulating
application
individual
thermal shock
Prior art date
Application number
EA200300438A
Other languages
English (en)
Other versions
EA005821B1 (ru
Inventor
Альберто Мартини
Сальваторе Альбани
Деннис Карсон
Берент Дж. Праккен
Original Assignee
Дзе Реджентс Оф Дзе Юниверсити Оф Калифорния
Альберто Мартини
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Реджентс Оф Дзе Юниверсити Оф Калифорния, Альберто Мартини filed Critical Дзе Реджентс Оф Дзе Юниверсити Оф Калифорния
Publication of EA200300438A1 publication Critical patent/EA200300438A1/ru
Publication of EA005821B1 publication Critical patent/EA005821B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Описан способ модуляции иммунного ответа у индивидуума. Изобретение основано на открытии того, что эффективная терапевтическая стратегия в уменьшении интенсивности связанных с воспалением симптомов опосредованного иммунитетом заболевания, такого как артрит, может быть осуществлена путём модуляции самого лежащего в основе иммунного ответа, а не нацеливанием только на являющееся конечным результатом воспаление. Эта стратегия может быть использована для регуляции воспалительной реакции и применима ко многим ситуациям, в которых требуется иммунная модуляция, к таким как стимуляция толерантности в слизистой оболочке, ДНК-вакцинация, индуцирование анергии, активная иммунизация и модуляция ex vivo антиген-специфических Т-клеток. В одном из вариантов осуществления способ включает введение индивидууму пептида бактериального dnaJ, или его человеческого гомолога, или его негомологичной человеческой изоформы.Отчет о международном поиске был опубликован 2003.08.21.
EA200300438A 2000-11-01 2001-10-31 Иммуномодулирующие пептиды, полученные из белков теплового шока, и их применение EA005821B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24518100P 2000-11-01 2000-11-01
PCT/US2001/045344 WO2002036611A2 (en) 2000-11-01 2001-10-31 Immunomodulatory peptides derived from heat shock proteins and uses thereof

Publications (2)

Publication Number Publication Date
EA200300438A1 true EA200300438A1 (ru) 2003-12-25
EA005821B1 EA005821B1 (ru) 2005-06-30

Family

ID=22925623

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300438A EA005821B1 (ru) 2000-11-01 2001-10-31 Иммуномодулирующие пептиды, полученные из белков теплового шока, и их применение

Country Status (13)

Country Link
US (2) US7301005B2 (ru)
EP (1) EP1355923B1 (ru)
JP (1) JP4264257B2 (ru)
KR (1) KR20030055295A (ru)
CN (1) CN1481390B (ru)
AT (1) ATE548376T1 (ru)
AU (1) AU2002220038A1 (ru)
BR (1) BR0115246A (ru)
CA (1) CA2427572A1 (ru)
EA (1) EA005821B1 (ru)
IL (1) IL155610A0 (ru)
MX (1) MXPA03003901A (ru)
WO (1) WO2002036611A2 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006052773A2 (en) * 2004-11-07 2006-05-18 Androclus Therapeutics Inc. Treatments for demyelinating immune mediated diseases
WO2007140287A2 (en) * 2006-05-25 2007-12-06 Dr. Reddy's Laboratories, Inc. Use of biomarkers of inflammation as indicators of drug efficacy
AT504685B1 (de) * 2006-12-20 2009-01-15 Protaffin Biotechnologie Ag Fusionsproteine
JP2010532785A (ja) 2007-07-06 2010-10-14 ウニベルジテイト・ウトレヒト・ホールディング・ビー．ブイ． 炎症性疾患および自己免疫疾患の治療および予防
PL2598165T3 (pl) * 2010-07-26 2018-02-28 Qu Biologics Inc. Immunogenne kompozycje przeciwzapalne
RU2483746C1 (ru) * 2012-05-17 2013-06-10 Федеральное государственное унитарное предприятие "Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" (ФГУП "ГНЦ "НИОПИК") Средство для антиагрегатной, антивоспалительной и цитопротекторной терапии
KR101632948B1 (ko) * 2014-05-13 2016-06-27 (주)케어젠 항염증, 골 형성 및 발모 촉진 활성을 갖는 펩타이드 및 이의 용도
KR20190028662A (ko) 2016-05-25 2019-03-19 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 면역요법의 방법
AR114683A1 (es) * 2018-02-09 2020-10-07 Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet Polipéptidos inmunomoduladores e inmunoestimulantes para suministro de drogas
GB201807831D0 (en) * 2018-05-15 2018-06-27 Univ College Cardiff Consultants Ltd Cancer Vaccine

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732757A (en) 1978-02-06 1988-03-22 Stolle Research And Development Corporation Prevention and treatment of rheumatoid arthritis
US4683295A (en) 1984-05-24 1987-07-28 Scripps Clinic And Research Foundation Method for the preparation of anti-receptor antibodies
US4654419A (en) 1984-08-08 1987-03-31 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to epstein-barr virus nuclear antigen
US5116725A (en) 1984-08-08 1992-05-26 Scripps Clinic And Research Foundation Assay for Epstein-Barr virus infection with solid phase bound synthetic polypeptides
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
WO1990014835A1 (en) 1989-05-31 1990-12-13 Scripps Clinic And Research Foundation Method to treat rheumatoid arthritis
AU651949B2 (en) * 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
US5891435A (en) 1993-04-16 1999-04-06 Research Corporation Technologies, Inc. Methods and compositions for delaying or preventing the onset of autoimmune disease
US5728385A (en) 1993-08-12 1998-03-17 Classen Immunotherapies, Inc. Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae
JPH10500679A (ja) 1994-05-20 1998-01-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 慢性関節リウマチを治療するための方法および試薬
US5773570A (en) * 1994-05-20 1998-06-30 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
US5993803A (en) 1996-08-30 1999-11-30 Yeda Research And Development Co., Ltd. Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
DE19702065C1 (de) * 1997-01-22 1998-05-20 Kurzik Dumke Ursula Dr Polyklonaler Antikörper zum Nachweis des tumorassoziierten Antigens hTid
US6007821A (en) 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US5992567A (en) 1999-01-29 1999-11-30 Chiu; Ping-Jan Foldable frame

Also Published As

Publication number Publication date
IL155610A0 (en) 2003-11-23
US7301005B2 (en) 2007-11-27
WO2002036611A3 (en) 2003-08-21
EP1355923B1 (en) 2012-03-07
BR0115246A (pt) 2005-04-26
KR20030055295A (ko) 2003-07-02
US20030031679A1 (en) 2003-02-13
CA2427572A1 (en) 2002-05-10
AU2002220038A1 (en) 2002-05-15
JP4264257B2 (ja) 2009-05-13
EA005821B1 (ru) 2005-06-30
ATE548376T1 (de) 2012-03-15
EP1355923A2 (en) 2003-10-29
WO2002036611A2 (en) 2002-05-10
CN1481390A (zh) 2004-03-10
MXPA03003901A (es) 2004-09-10
JP2004537496A (ja) 2004-12-16
CN1481390B (zh) 2010-12-22
US20080187550A1 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
DE69332434D1 (de) Clostridium perfringens Impfstoffe
CY1121353T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
EP0692031A4 (en) HETEROLOGIST ANTIGENES IN STRAINS FOR VACCINATION WITH LIVING CELLS
EA200300438A1 (ru) Иммуномодулирующие пептиды, полученные из белков теплового шока, и их применение
RU2011105448A (ru) Применение ингибирующих tgf-бета1 пептидов для приготовления модулирующего иммунный ответ агента
DE69532760D1 (de) Mittel zur verabreichung von antigenen
ATE244891T1 (de) Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope
ATE510851T1 (de) Auf peptiden basierende immunisierungstherapie zur behandlung von atherosklerose
TR199801722T2 (xx) Peptit imm�nojenler.
ATE328073T1 (de) Ehrlichia canis protein
Kim et al. Antimicrobial peptide LL‐37 promotes antigen‐specific immune responses in mice by enhancing Th17‐skewed mucosal and systemic immunities
PE20050962A1 (es) Anticuerpos completamente humanos contra 4-1bb humano
ES2168456T3 (es) Peptidos que afectan a los linfocitos t.
ATE404217T1 (de) Therapie mit lipoproteinlipase (lpl) variant
Maletto et al. CpG oligodeoxinucleotides functions as an effective adjuvant in aged BALB/c mice
WO1996018646A3 (en) Heat shock protein peptides and methods for modulating autoimmune central nervous system disease
RU2004108115A (ru) Рекомбинантные антитела и композиции, а также способы их создания и использования
FR2781158B1 (fr) Nouvelles proteines modifiees immunogenes non immunosuppressives, leur procede de preparation et leurs applications
BG99074A (bg) Рекомбинантни човешки нiv-неутрализиращи моноклонални антитела за профилактика и лечение на нiv инфекция
CN1134112A (zh) 衣原体感染的疫苗及治疗方法
ES2134474T3 (es) Peptidos utilizados como agentes terapeuticos para el tratamiento de enfermedades autoinmunitarias.
Abdel Aziz et al. Immunogenicity and protective capacity of Schistosoma haematobium recombinant cathepsin L against infection of hamsters with S. haematobium
AU7520398A (en) Test kit for tuberculosis diagnosis or the like
DE69629304D1 (de) Membranproteine von leptospira
FR2694938B1 (fr) Nouveaux peptides, anticorps diriges contre ces peptides, anticorps anti-idiotypiques, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU